BIOGRAPHICAL SKETCH

					                                                       BIOGRAPHICAL SKETCH
            Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
                                       Follow this format for each person. DO NOT EXCEED FOUR PAGES.

 NAME                                                                         POSITION TITLE
 Chen, Chu-Huang                                                              Director/Professor
 eRA COMMONS USER NAME
 chchen1
 EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
                                                                              DEGREE
                  INSTITUTION AND LOCATION                                                        YEAR(s)                  FIELD OF STUDY
                                                                           (if applicable)
 Kaohsiung Medical College, Kaohsiung, Taiwan                                M.D.                1978                        Medicine
 Chang-Gung Memorial Hospital, Taipei, Taiwan                              Resident            1978-1981                    Pathology
 Texas Tech University, Lubbock, Texas                                      Ph.D.                1986                       Physiology
 Maryland General Hospital & Univ. of Maryland                             Resident            1986-1989                Internal Medicine
 Baylor College of Medicine, Houston, Texas                                 Fellow             1989-1992                    Cardiology


A. Positions and Honors
Professional Experience
1992-1993        Postdoctoral Associate, Section of Atherosclerosis/Medicine, Baylor College of
                 Medicine
1993-1994        Instructor of Medicine, Baylor College of Medicine, Houston, Texas
1994-2004        Assistant Professor of Medicine, Baylor College of Medicine, Houston, Texas
2004-            Associate Professor of Medicine, Baylor College of Medicine, Houston, Texas
2006-            Clinical Director, Behavioral Medicine Research Center, Department of Medicine, Baylor
                  College of Medicine, Houston, Texas
2009-            Professor and Director, Vascular and Medicinal Research, Wafic Said Molecular Cardiology
                  Research Laboratories, Texas Heart Institute at St. Luke’s Hospital, Houston, Texas
Honors and Awards
1) Tar box Fellowship, Texas Tech University, 1983 to 1986
2) The Methodist Hospital Foundation Award, 1993 to 1994
3) The Virginia and Ernest Cockrell Jar Award, 1994
4) Zeneca Pharmaceuticals Research Award, 1993 to 1995
5) AHA, Texas Affiliate, Grant-In-Aid, 1995 to 1997
6) Texas Medical Center/NASA Cooperative Research Grant, 1995 to 1996
7) AHA, National, Scientist Development Award, 1997 to 2000
8) The Atorvastatin Research Award, 1999 to 2000
9) American Diabetes Association Research Award, 2000 to 2003
10) Pfizer Independent Medical Grant, 2002-2003
11) American Diabetes Association Research Award, 2004 to 2006
12) Pfizer Independent Medical Grant, 2004-2005
13) Philip Morris Research Award, 2005-2008
14) AHA grant reviewer, Western Review Consortium, 2004-2008.
Honors as a Mentor
1) Postdoctoral Fellow, Jeffrey P. Walterscheid, Ph.D., AHA Fellowship, 2006
2) Postdoctoral Fellow, Daming Tang, M.D., Ph.D., NIH Training Grant, 2007


                                                                          1
Memberships in Professional Societies
1) American Diabetes Association
2) AHA, Atherosclerosis Council
3) International Atherosclerosis Society
4) American Association for the Advancement of Science
5) The Angiogenesis Society

B. Publications
Selected peer-review publications (in reversed order) *corresponding author
Published
Chang PY, Lu SC, Lee YT, Chen CH*. Comment on: Song et al. (2009) Effect of homocysteine-lowering
    treatment with folic acid and B vitamins on risk of type 2 diabetes in women: Diabetes 58:1921-1928.
    Diabetes. 2009; in press.
Wang GJ, Lin YL, Chen CH, Wu XC, Liao JF, Ren J. Cellular calcium regulatory machinery of vasorelaxation
    elicited by petasin. Clin Exp Pharmacol Physiol. 2009 Aug 28. [Epub ahead of print]
Chen CH*, Dixon RAF, Ke LY, Willerson JT. Vascular progenitor cells in diabetes mellitus: Roles of Wnt
    signaling and negatively charged LDL. Circ Res. 2009;104:1038-1040.
Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP, Suzuki S, Yang CY, Sawamura T, Chen CH*.
    Mediation of electronegative LDL signaling by LOX-1: A possible mechanism of endothelial apoptosis.
    Circ Res. 2009;104:619-627.
Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH Chang SF, Liao WS, Chen CH**, Lee YT.
    Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast
    growth factor-2 involving G protein and DNA methylation. Circ Res. 2008;102:933-941. (**senior author
    de facto, though not appearing as corresponding author)
Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH, Marcelli M, Tang D, Lee YT, Liao WSL, Yang
    CY, Chen CH*. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting
    FGF2 autoregulation. Diabetes. 2008;57:158-166.
Tang D, Lu J, Walterscheid JP, Chen HH, Engler DA, Sawamura T, Chang PY, Safi HJ, Yang CY, Chen CH*.
    Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting
    Akt phosphorylation via LOX-1. J Lipid Res. 2008;49:33-47.
Yang CH, Chen HH, Huang MT, Raya JL, Yang JH, Chen CH, Gaubatz JW, Pownall HJ, Taylor AA,
    Ballantyne CM, Jenniskens FA, Smith CV. Pro-apoptotic low-density lipoprotein subfractions in type II
    diabetes atherosclerosis. Atherosclerosis. 2007;193:283-91.
Cheng J, Cui R, Chen CH, Du J. Oxidized low-density lipoprotein stimulates p53-dependent activation of
    proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells. Endocrinology.
    2007;485:2085-2094.
Chen CH*, Walterscheid JP. Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. Circ
    Res. 2006;99:787-789.
Chen CH*. Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidol.
    2004;15:337-341.
Chen CH*, Poucher SM, Lu J, Henry PD. Fibroblast growth factor 2: From laboratory evidence to clinical
    application. Curr Vasc Pharmacol. 2004;2:33-43 (figure used for cover page).
Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, Chen CH, Liau CS, Lee YT. Lipoprotein-X
    reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res.
    2004;45:2116-2122.
Chen CH*, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, McIntyre TM, Henry
    PD, Yang CY. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular
    endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation.
    2003;107:2102-2108.
                                                       2
Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, Pownall HJ, Taylor AA, Smith CV. Isolation,
    characterization, and functional assessment of oxidatively modified subfractions of circulating low-density
    lipoproteins. Arterioscler Thromb Vasc Biol. 2003;23:1083–1090.
Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD, Chen CH*. Oxidized low-density lipoprotein
    downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein
    pathway: mediator role of platelet-activating factor-like phospholipids. Circulation. 2001;104:588-593.
Chen CH*, Jiang W, Via D, Luo S, Li TZ, Lee YT, Henry PD. Oxidized low-density lipoproteins inhibit
    endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation.
    2000;101:171-177.
Chen CH*, Volding D. Medicinal foods: cross cultural perspectives. In Food As A Drug, edited by Poston
    WSC. 2000. P. 49–64.
Chen CH*, Volding D. Medicinal foods: cross cultural perspectives. Drugs and Society. 1999;15:49-64.
Bucay M, Nguy J, Barrios R, Chen CH, Henry PD. Impaired adaptive vascular growth in hypercholesterolemic
    rabbit. Atherosclerosis. 1998;139:243-251.
Chen CH*, Cartwright J Jar, Li Z, Luo S, Nguyen HH, Gotto AM Jar, Henry PD. Inhibitory effects of
    hypercholesterolemia and oxidized LDL on angiogenesis-like endothelial growth in rabbit aortic explants:
    essential role of basic fibroblast growth factor. Arterioslcer Thromb Vasc Biol. 1997;17:1303-1312.
Chen CH*, Henry PD. Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by
    suppressed basic fibroblast growth factor expression. Proc Assoc Am Physicians. 1997;109:351-361.
Chen CH*, Nguyen HH, Weilbaecher D, Luo S, Gotto AM Jar, Henry PD. Basic fibroblast growth factor
    reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro.
    Atherosclerosis. 1995;116:261-268.
Henry PD, Cabello OA, Chen CH. Hypercholesterolemia and endothelial dysfunction. Curr Opin Lipidol.
    1995;6:190-195.
Chen CH*, Williams J, Lutherer LO. 1994. Cerebellar lesions alter autonomic responses to transient isovolemic
    changes in arterial pressure. Clin Auton Res. 1994;4:263-272.
Henry PD, Chen CH. Inflammatory mechanism of atheroma formation: influence of fluid mechanics and lipid-
    derived inflammatory mediators. Am J Hypertens. 1993;6(suppl):328-334.
Chen CH, O'Leary EL, Janssen HF, Lutherer LO. 1985. Changes in ambient temperature alter the blood pressure
    response to endotoxin and the effectiveness of naloxone. Circ Shock. 1985;16:185-193.
Schoenfeld AD, Lox CD, Chen CH, Lutherer LO. Pain threshold changes induced by acute exposure to ambient
   temperature. Peptides. 1985;6 (suppl 1):19-22.
Lutherer LO, Smith AL, Chen CH, O'Leary EL, Lutherer BC. The effect of angiotensin and vasopressin blockade
   separately and in combination with cerebellectomy on recovery from hemorrhagic hypotension. Circ Shock.
   1983;10:329-340.
Chen L, Chen CH. Cardiac myxomas: a report of two cases. Modern Medicine in Asia. 1980;16(12), December.

Soon to be submitted, being edited
Tang D, Lu J, Chen HH, Engler DA, Sawamura T, Chu CS, Pownall HJ, Wang GJ, Yang CY, Dixon RAF,
    Chen CH*. Negatively charged LDL enhances matrix metalloproteinase-2 mediated activities of
    endothelial progenitor cells. Circ Res.
Chen CY, Tang D, Hsu HC, Chow LP, Yang CY, Burns AR, Lee YT, Chen CH*. Proteomic detection of
    endothelial stresses induced by electronegative LDL. Arterioscler Thromb Vasc Biol.

Most recent abstract presentations on related subjects at national meetings
Chen CH*, Lu J, Wang GJ, Dixon RAF, Yang CY, Willerson JT. Mechanistic basis of L5 as a novel treatment
   target for coronary artery disease. 8th International Congress on Coronary Artery Disease. Prague,
   Czech Republic. October 11–14, 2009.


                                                       3
Chang PY, Lee JK, Chen YJ, Lu SC, Lee YT, Chang KC, Pai PY, Chen CH. Identification of an
    electronegative LDL as potential novel biomarker for acute coronary syndrome. European Society of
    Cardiology Congress. Barcelona, Spain. August 29–September 2, 2009.
Tang D, Burns AR, Lu J, Chen HH, Wu H, Morrisett JL, Sawamura T, Yang CY, Chen CH*. Electronegative
    LDL disrupts mitochondrial homeostasis: a novel mechanism for cigarette smoking-associated endothelial
    dysfunction. Presented at the FASEB 2008 meeting, San Diego, CA, April 5–9, 2008.
Tang D, Chen HH, Lu J, Engler DA, Sawamura T, Pownall HJ, Yang CY, Chen CH*. Chronic smoking-
    yielded electronegative LDL induces MEK/ERK mediated metalloproteinase activation in human
    endothelial progenitor cells. J Am Coll Cardiol. 2008;51(suppl A):A278. Presented at the American
    College of Cardiology 2008 Scientific Sessions, Chicago, IL, March 29–April, 2008.
Tang D, Lu J, Walterscheid JP, Chen HH, Yang JH, Engler DA, Sawamura T, Marcelli M, Yang CY, Chen
    CH*. Electronegative LDL in smoking subjects inhibits endothelial progenitor cell differentiation by
    impairing Akt phosphorylation via the LOX-1 receptor. Arterioscler Thromb Vasc Biol. 2007; Presented at
    the ATVB Annual Conference April 19-21, 2007 Chicago, IL.
Lu J, Walterscheid JP, Chen HH, Yang CY, Poucher SM, Chen CH*. Diabetic LDL subfraction induces
    smooth muscle cell proliferation by enhancing endothelial release of endothelin-1. Diabetes. 2006;55
    (suppl 1):A160. Presented at the American Diabetes Association 66th Scientific Sessions in Washington
    DC. June 9–13, 2006.
Lu J, Chen HH, Yang CY, Walterscheid JP, Pownall HJ, Morrisett JD, Chen CH*. C4 Platelet-activating factor
    mimics electronegative LDL circulating in patients with metabolic syndrome in inducing endothelial cell
    apoptosis. Diabetes. 2005;54(suppl 1):A193. Presented at the American Diabetes Association 65th
    Scientific Sessions in San Diego, CA, June 10–14, 2005.
Lu J, Yang JH, Chen HH, Yang CY, Henry PD, Walterscheid JP, Morrisett JD, Sawamura T, Chen CH*.
    Effective attenuation of electronegative LDL-induced endothelial cell apoptosis by gene silencing of the
    lectin-like receptor for oxidized LDL. J Am Coll Cardiol. 2005. Presented at the 54th American College of
    Cardiology Scientific Sessions in Orlando, FL, March 6–9, 2005.
Tai MH, Kuo SM, Huang MT, Yang JH, Chen HH, Lu J, Sawamura T, Chen CH, Yang CY. Activation of
    caspase 13 by diabetic electronegative LDL through lectin-like oxidized LDL receptor-1 (LOX-1) in
    vascular endothelial cells. Circulation. 2005;112:II-1105. Presented at the American Heart Association
    2005 Scientific Sessions, Dallas, TX, November 11-16, 2005.
Chang PY, Lu SC, Lee CM, Huang WH, Chen YJ, Liao WSL, Chen CH, Lee YT. Homocysteine impairs
    endothelial cell survival by repressing the transcriptional activity of the fibroblast growth factor 2 promoter.
    J Am Coll Cardiol. 2005. Presented at the 54th American College of Cardiology Scientific Sessions in
    Orlando, FL, March 6–9, 2005.
Lu J, Marcelli M, Liao WSL, Yang JH, Henry PD, Yang CY, Pownall HJ, Chen CH*. Dominant-negative Akt
    impairs endothelial cell survival by mimicking the inhibitory effect of electronegative LDL on FGF2
    transcription. Circulation. 2004;110-III87. Presented at the American Heart Association 2004 Scientific
    Sessions, New Orleans, LA, November 7-10, 2004.
Chen CH*, Pace PW, Karakoc ND, Lu J, Chen HH, Henry PD, Pownall HJ, Foreyt JP, Ballantyne CM, Yang
    CY. Effective reduction of novel atherogenic LDL subfraction by atorvastatin in patients with
    hypercholesterolemia. J Am Coll Cardiol. 2004;43(suppl A):486A. Presented at the 53rd American College
    of Cardiology Scientific Sessions in New Orleans, LA, March 7–10, 2004.
Lu J, Chen HH, Suzuki S, Yang CY, Henry PD, Sawamura T, Chen CH*. Role of the LOX-1 receptor in
    transducing the apoptotic signals of circulating atherogenic LDL. J Am Coll Cardiol. 2004;43(suppl
    A):26A. Presented at the 53rd American College of Cardiology Scientific Sessions in New Orleans, LA,
    March 7–10, 2004.
Jiang W, Lu J, Yang JH, Chang PY, Lee YT, Marcelli M, Henry PD, Liao WSL, Chen CH*. Atherogenic LDL
    impairs vascular endothelial cell survival by disrupting the FGF2-PI3K-Akt autoregulatory loop. J Am Coll


                                                         4
    Cardiol. 2004;43(suppl A):499A. Presented at the 53rd American College of Cardiology Scientific
    Sessions in New Orleans, LA, March 7–10, 2004.
Lu J, Marathe GK, Yang CY, Jiang W, Yang JH, Pownall HJ, Henry PD, Chen CH*. Platelet-activating factor-
    like lipids mediate endothelial cell apoptosis induced by hypercholesterolemic LDL. J Am Coll Cardiol.
    2003;41(Supple):243A. Presented at the 52nd American College of Cardiology Scientific Sessions in
    Chicago, IL, March 30–April 2, 2003.
Chen CH*, Jiang T, Yang JH, Jiang W, Pownall HJ, Ballantyne CM, Lu J, Henry PD, Yang CY. Induction of
    vascular endothelial cell apoptosis through the platelet-activating factor receptor in hypercholesterolemia.
    Atherosclerosis. 2002;3:88. Presented at the 73rd European Atherosclerosis Society Congress, Salzburg,
    Austria, July 7-10, 2002.
Lu J, Suzuki S, Safi HJ, Jiang W, Henry PD, Yang JH, Morrisett JD, Chen CH*. OxLDL LDL-induced
    vascular endothelial cell apoptosis involves ceramide-mediated Akt dephosphorylation: protective role of
    FGF2 overexpression. Atherosclerosis. 2002;3:88. Presented at the 73rd European Atherosclerosis Society
    Congress, Salzburg, Austria, July 7-10, 2002.
Jiang W, Lu J, Chang PY, Yang JH, Henry PD, Marcelli M, Chen CH*. Oxidized LDL induces endothelial cell
    apoptosis by impairing the FGF2-PI3K-Akt pathway. Circulation. 2002;105:e86-e119. Presented at the
    American Heart Association-Asia Pacific Scientific Forum, Honolulu, Hawaii, April 23-26, 2002.
Lu J, Suzuki S, Safi HJ, Jiang W, Henry PD, Yang CY, Chen CH*. FGF2 overexpression prevents ceramide-
    mediated Akt deactivation in endothelial cells exposed to oxidized LDL. Arterioscler Thromb Vasc Biol.
    2002;22:878-a. Presented at the American Heart Association-3rd Annual ATVB council meeting, Salt Lake
    City, Utah, April 6-8, 2002.
Chen CH*, Yang JH, Morrisett JD, Lu J, Jiang T, Henry PD, Yang CY. Proapoptotic activity of a novel LDL
    subfraction in hypercholesterolemic human plasma. Circulation. 2001;104:II297. Presented at AHA 2001
    Scientific Sessions 2001 of the American Heart Association, Anaheim, CA, November 11-14, 2001.
Chen CH*, Yang JH, Luo S, Chang PY, Gross R, Wu S, Henry PD. Oxidized LDL-induced endothelial cell
    apoptosis: role of mediator phospholipids and bFGF. Atherosclerosis. 2000;151:215. Presented at the XIIth
    International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000.

C. Research Support
a) Ongoing Research Support
1. Research Award PI: Chen, Chu-Huang                               03/01/102/28/13
Philip Morris International
Mechanisms of smoker L5-induced endothelial dysfunction
The goal is investigate the molecular and in vivo mechanisms of endothelial dysfunction induced by L5 isolated
from chronic smokers and from rats and mice exposed to cigarette smoke.
2. Research Award PI: Chen, Chu-Huang                               09/01/0512/31/09
Philip Morris Inc.
Atherogenic mechanisms and potential treatments of a highly electronegative, mildly oxidized low-density
lipoprotein subfraction circulating in smoking subjects
The goal is to analyze atherogenic LDL subfractions in the plasma of smoking subjects and to examine whether
these LDL subfractions can be eliminated or reduced pharmacologically.
3. RO-1 U01 DK-57177                         PI: Foreyt, John P.    09/01/200108/31/2012
National Institutes of Health/NIDDK
Lookahead: Study of Health Outcomes of Weight-Loss
Role: Co-investigator
4. Training Grant T32 HL07812-0181           PI: Morrisett, Joel D. 07/01/199707/31/11
National Institutes of Health
Training Grant in Atherosclerosis and Vascular Biology

                                                       5
The major goals of this project are to equip a cadre of bright, young biomedical scientists with the skills that
will enable them to conduct state-of-the-art basic and clinical research in the area of atherosclerosis/vascular
biology. The ultimate goal is to train both predoctoral students and postdoctoral fellows to develop new,
creative and effective approaches for the prevention and treatment of atherosclerosis.
Role: Co-investigator
5. Independent Medical Research Grant         PI: Chen, Chu-Huang 9/01/0812/31/10
Merck-Schering Plough Pharmaceuticals
Effects of Ezetimibe and Vytorin on Reducing L5 in Patients with Metabolic Syndrome
6. Multi-center clinical trial                PI: Foreyt, John P. 01/01/06 – 12/31/09
Sanofi-Aventis, US, Inc.
 Protocol No. EFC5107 – A Randomized, Double-Blind, Placebo-Controlled, Multicenter study to assess the
efficacy and safety of long-term administration of rimonabant in the prevention of Type 2 Diabetes in Patients
with prediabetic status.
Role: Co-investigator
b) Completed Research Support (recent)
1. Research Award, #1-04-RA-13                PI: Chen, Chu-Huang           01/01/0412/31/06
American Diabetes Association
Phospholipid-mediated vascular endothelial cell apoptosis in hyperlipidemia (in patients with diabetes)
The major goal is to determine the mechanism of EC apoptosis induced by diabetic LDL.
2. Independent Medical Research Grant         PI: Chen, Chu-Huang          01/01/0412/31/05
Pfizer Pharmaceuticals
Role of electronegative LDL in left ventricular hypertrophy and acute coronary syndromes: Efficacy of
atorvastatin in reducing LV mass and risk of sudden cardiac death
The goal is to determine whether electronegative LDL is associated with increased LV mass and sudden cardiac
death.
3. Multi-center clinical trial                PI: Foreyt, John P.          01/01/07 – 12/31/2008
Orexigen Therapeutics
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Comparing the Safety and Efficacy of
Naltrexone Sustained Release (SR)/ Bupropion Sustained Release (SR) and Placebo in Subjects with Obesity
Participating in a Behavior Modification Program.
Role: Co-investigator
c) Pending Research Support
1. R01 (new submission)                       PI: Chen, Chu-Huang          7/01/20106/30/2015
National Institutes of Health
Novel lipid mechanism of endothelin 1–nitric oxide disequilibrium in diabetes
The goal is to delineate the molecular mechanism of the functional imbalance between ET-1 and NO, which has
a tremendous implication in diabetic vasculopathy.
2. R01 (new submission)                       PI: Chen, Chu-Huang          12/01/200911/30/2014
National Institutes of Health
In vitro evidence and in vivo relevance of L5 in cardiovascular disease
The goal is to further delineate the molecular mechanism and to define the in vivo relevance of L5 in
cardiovascular disease.
3. R21 (resubmission)                         PI: Chen, Chu-Huang          6/01/20105/31/2012
National Institutes of Health
Characterization and epidemiologic investigation of a novel electronegative VLDL in diabetic and prediabetic
populations
The goal is to characterize and assess the prevalence of a novel VLDL subfraction in diabetic and prediabetic
subjects.
d) Grants in preparation
                                                         6
1. RO1 (new submission)                     PI: Chen, Chu-Huang       4/01/201011/30/2015
National Institutes of Health
Use of a smart oxidized LDL-nanohybrid to treat oral cancers
The goal is to evaluate the effectiveness of a nanohybrid composed of oxLDL and a nanocarrier in treating
cancers both ex vivo and in vivo.

2. RO1 (new submission)                     PI: Chen, Chu-Huang          4/01/201011/30/2015
National Institutes of Health
Mechanism of negatively-charged LDL formation
The goal is to investigate the mechanism of L5, a highly negatively charged LDL, formation by use of in vitro
and in vivo models.

3. Research Award                            PI: Chen, Chu-Huang         7/01/20096/30/2011
Merck/Schering-Plough Pharmaceuticals
Effects of Ezetimibe in reducing negatively charged VLDL
V5, a highly negatively charged VLDL subfraction is very toxic to vascular cells. The goal is to evaluate the
effectiveness of Zetia (Ezetimibe) in reducing V5’s formation and/or accumulation.

4. Research Award                             PI: Chen, Chu-Huang       7/01/20096/30/2011
Merck Pharmaceuticals
Mechanisms of niacin in increasing HDL
The goal is to investigate how niacin increases HDL.

5. Research Award                         PI: Chen, Chu-Huang       7/01/20096/30/2011
Forest Laboratories
Novel antihypertensive mechanisms of Nebivolol
The goal is to delineate new mechanisms beyond what is already known that underlines the antihypertensive
effects of Nebivolol.

D. Invited Lectures (recent)
1. L5—Our new direction. Kaohsiung Medical University Hospital Cardiovascular Science Symposium 2009,
    Kaohsiung, Taiwan, December 20, 2009.
2. When LDL becomes negatively charged. Graduate Institute of Biomedical Sciences, Chang Gung
    University, Seminar Series, Taipei, Taiwan, December 18, 2009.
3. When ―bad cholesterol‖ takes a further negative spin. THI/UT/MDACC Cardiovascular Research Seminar
    Series, Houston, Texas, December 3, 2009.
4. Mechanism of L5 formation stimulated by chronic smoking. Philip Morris International Research Center at
    Leuven, Belgium, October 16, 2009.
5. Smoker L5 induced endothelial dysfunction. Philip Morris International Research Center at Cologne,
    Germany, October 15, 2009.
6. Cardiovascular Disease & Stroke Cardiovascular Conference: Mechanistic basis of L5 as a novel treatment
    target for coronary artery disease. Texas Tech University Health Sciences Center. Lubbock, Texas, August
    20, 2009.
7. Topnotch Research Projects Strategic Conference: L5 as a causative factor for and marker of coronary
    artery disease. China Medical University Hospital, Taichung, Taiwan, July 15, 2009.
8. Targeted prevention of tobacco-associated atherosclerosis. Philip Morris International Special Lecture
    Invitation. Neuchatel, Switzerland, May 27, 2009.
9. Atherosclerosis and Vascular Biology Training Center Research Seminar Series, Baylor College of
    Medicine; October 9, 2008: L5—Functional properties and clinical implications
                                                        7
10. The 26th World Chinese Trader Convention, Special Lecture Series, New York, New York; September 14,
    2008: Electronegative LDL—A new mechanism and treatment target for cardiovascular disease
11. Cardiovascular Basic Science Seminar, Baylor College of Medicine; September 9, 2008: Electronegative
    LDL—What is it, who has it, what does it do to you?
12. The 8th Annual Emerging Information and Technology Conference (EITC-2008), National Cheng Kung
    University; June 26–27, 2008. Invited lecture: New mediators of smoking-incurred endothelial progenitor
    dysfunction
13. Institutional Grand Round, National Research Institute of Chinese Medicine, Taipei, Taiwan; June 24, 2008:
    Why is Smoking Bad for You? New Clues to an Old Enigma
14. Cardiology Section Grand Round, Chang-Gung Memorial Hospital, Taipei, Taiwan; June 23, 2008: Why is
    Smoking Bad for You? New Clues to an Old Enigma
15. Department of Medicine Grand Round, China Medical University, Taichung, Taiwan; June 20, 2008:
    Atherogenicity of Electronegative LDL—New Mechanism of Smoking-Incurred Endothelial Progenitor
    Dysfunction
16. American Heart Association, Western Review Consortium Study Group 4A Grant review meeting; Los
    Angele, LA, April 15-16, 2008
17. 1st International Conference on Drug Design and Discovery, Dubai, UAE; February 4-7, 2008. Session
    Lecture: New drug development following characterization of a novel atherogenic lipoprotein
18. The Seventh Annual Emerging Information and Technology Conference (EITC-2007), Princeton
    University, New Jersey; June 9-10, 2007. Invited speech: The potential anticancer effects of electronegative
    LDL, a biological nanoparticle
19. Kaohsiung Medical University Hospital 50th Anniversary Cardiovascular Symposium, Kaohsiung, Taiwan;
    June 10, 2007, Keynote Speech: Structural characterization and signal mapping of electronegative LDL
20. American Heart Association, Western Review Consortium Study Group 4A Grant review meeting; Houston,
    Texas; April 18-19, 2007
21. 2006 World Congress of Internal Medicine, November 10-13, 2006, Taipei, Taiwan; Symposium:
    Hyperlipidemia and Cardiovascular Diseases: Clinical Challenge in IT Era; Invited Lecture: New Strategies
    of LDL Lowering: From Bench to Clinical Work
22. The Sixth Annual Emerging Information Technology Conference (EITC-2006), University of Texas at
    Dallas; August 10-11, 2006. Invited speech: What is L5, a recently discovered biological nanoparticle, and
    how does it affect your health?
23. Department of Molecular and Cellular Oncology, UT-MD Anderson Cancer Center; May 31, 2006. Invited
    seminar: L5, a circulating lipoprotein that erodes your arteries
24. American Heart Association, Western Review Consortium Study Group 4A Grant review meeting; Salt
    Lake City, Utah,; April 18-19, 2006
25. Atorvastatin Research Award (ARA) Summit Meeting, February 10-12, 2006, Salt Lake City, Utah; Invited
    speech: Introductory Talk for the Summit: The ARA and My Career Development




                                                       8

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:6
posted:7/5/2011
language:English
pages:8